Nitracrine (C 283)

01/01/1973 - "Therapeutic efficacy of compound C-283 in patients with mammary carcinoma."
01/01/1972 - "Biochemical blood studies in patients with carcinoma of the ovaries during treatment with preparation C-283. "
01/01/1972 - "Biochemical blood studies in patients with ovarian carcinoma treated with C-283. "
01/01/1971 - "Biochemical blood studies in patients with carcinoma of the ovaries during treatment with preparation C-283. "
01/01/1983 - "Ledakrin in treatment of patients with carcinoma of the lung."

08/01/2002 - "In this study, cell cycle perturbations, effects on DNA synthesis and the cell death process initiated by Nitracrine were studied in murine leukemia L1210 cells. "
01/01/1994 - "Thiol dependent inhibition of mouse leukemia L1210 DNA topoisomerase I by nitracrine."
11/01/1987 - "For seven new methoxy and/or nitro derivatives of acridine antitumor drugs, nitracrine and amsacrine, biological activity in a few in vitro tests, as well as activity against experimental murine tumors Sarcoma-180 and Leukemia L1210 were investigated. "
11/15/1989 - "Ledakrin [1-nitro-9-(3'-dimethylamino-N-propylamino)acridine], an antitumor drug of the 1-nitro-9-aminoacridine family, was able to induce DNA-protein crosslinks in intact L1210 leukemia cells, as demonstrated by the potassium-dodecyl sulfate precipitation technique. "

01/01/1976 - "[Antiviral effects of acridine derivative C 283 in Herpes simplex studies]."

06/21/1996 - "The parent compound 2 was selectively toxic to hypoxic cells in KHT tumors in vivo and clearly superior to nitracrine itself (although only at doses which would eventually be lethal to the host). "
05/01/1990 - "II. Features of nitracrine analogs for high anti-tumor activity and selectivity on mice, searched by PCA and MRA methods."
04/01/1990 - "Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors."
01/01/1989 - "The nitroacridine derivative 9-[[3-(dimethylamino)propyl]amino]-1-nitroacridine (nitracrine) is selectively cytotoxic to hypoxic tumor cells in culture. "
01/01/1982 - "None of the tested compounds, including Ledakrin, revealed anti-tumor activity. "

05/01/1990 - "In an attempt to modulate the degree of hypoxia selectivity among this class of compounds, we have studied a series of side-chain analogues of nitracrine. "
05/01/1990 - "4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis"."
05/01/1989 - "To determine whether it is possible to separate antitumour and mutagenic properties in the nitracrine series, a number of 4-substituted derivatives of the hypoxia-selective drug nitracrine have been evaluated for their mutagenic effects at three loci in several strains of Salmonella typhimurium differing in DNA-repair capacity (uvrB, recA, plasmid pKM101). "
01/01/1989 - "Nevertheless, comparison of the kinetics of the killing of AA8 cells under hypoxia suggests that some metabolic stabilization of the compounds can be achieved by the use of electron-donating substituents, with such compounds retaining the hypoxia-selective toxicity of nitracrine in cell culture. "
01/01/1989 - "1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine."